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Summary To study the production and significance of prostacyclin (PGI2) and thromboxane A2 (TxA2) in
breast cancer, tissue fragments of breast cancer (n=23) and mastopathy (n= =10) were superfused in vitro and
the release of 6-keto-PGFlalpha (a metabolite of PG12) and TxB2 (a metabolite of TxA2) measured by
radioimmunoassay. Breast cancer formed more 6-keto-PGFlalpha (4.5 +0.9ngmin-1g- of tissue dry weight,
mean+s.e.) and TxB2 (2.5+0.6ngmin-1g-1) (P<0.01) than did mastopathic breast (1.4+0.5 and
0.4+0.1 ngmin-' g-, respectively). These productions were similar in steroid receptor positive and negative
tumours. Breast cancer metastasized in 15 patients during the follow-up time of 3.7+0.7 years, but the initial
prostanoid productions in these patients were not different from those in nonmetastatic patients. Two patients
died from metastases, but their initial mammary production ofprostanoids was not profoundly different from
those in the survivors. In 8 patients (4 with steroid receptor positive and 4 with negative tumour), the cancer
tissue was superfused in the presence or absence of medroxyprogesterone acetate (100-5000ngml- 1), which is
commonly used for treatment of breast cancer. This hormone had no effect on mammary PGI2 and TxA2
production. We thus conclude that the PGI2 and TxA2 productions are increased in mammary cancer but
that this may not be ofprimary significance for metastastic spread.
It is well established that human breast cancer
produces increased amounts ofclassic prostaglandins
(PG) belonging to the E and F series (Bennett et
al., 1977; Rolland et al., 1980; Karmali et al.,
1983). This increase seems to be relative to the
cancers tendency to metastasize to the bones
(Bennett et al., 1977; Rolland et al., 1980).
Moreover, PGE may be responsible for the
hypercalcaemia often present in patients with bone
metastasis (Tashjian et al., 1978). Taken together,
these data suggest a role for classic PGs in the
metastasis of breast cancer. On the other hand,
circulating platelets may also be a factor in
metastatic spread because only the cancer cells
which bind platelets to their surface, may form a
metastasis (Marcum et al., 1982, Honn et al., 1983).
Therefore, antiaggregatory prostacyclin (PGI2) and
its endogenous antagonist, thromboxane A2
(TxA2), are of great interest in this regard and,
indeed, a dominance of PGI2 over TxA2 in the
circulation seems to decrease the risk of metastasis
in experimental animals (Honn et al., 1981; 1982).
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Because nothing is known about the significance of
the local production of these platelet active
prostanoids in breast cancer, we studied the
formation of PGI2 and TxA2 by metastatic and
nonmetastatic breast cancer. Also the effect of
medroxyprogesterone acetate (MPA an agent which
is commonly used for treatment of advanced breast
cancer, on the tumour PGI2/TxA2 was examined.
Materials and methods
Twenty-three patients with ductal adenocarcinoma
and ten women with benign mastopathy were
studied (Table I). Breast samples taken at surgery
were divided into two identical parts. One of them
was used for histologic examination of this sample
proved to be representative consisting mostly of
cancer cells, the other identical sample, which was
stored frozen in liquid nitrogen, was later used for
biochemical studies. These included the deter-
mination of oestrogen and progesterone receptors,
as described before (Vihko et al., 1980), and the
measurement of PGI2 and TxA2 production in
vitro with a tissue superfusion method (Makila et
al., 1982). Briefly, fragments of breast cancer or
noncancerous tissue (some 10-20mg of tissue dry
weight) were gently minced with scissors in Eagle's
medium (Gibco, Biocult 189 G, Paisley, UK.)
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Table I Clinical characteristics of the study population
(mean+s.e.)
Follow-up
Diagnosis N Age (years) time (years)
Ductal adenocarcinoma
all 23 60.4+2.7 3.7+0.7
Receptor positivea 11 66.7+4.2 4.7+ 1.4
Receptor negativeb 12 54.4+2.6 2.8+0.4
Poorly differentiated 16 61.5+3.3 3.5+0.8
Well differentiated 7 57.6+3.6 2.6+0.2
Metastasis 15 58.8i2.9 3.7+0.8
No metastasis 8 60.4+3.2 2.2+0.2
Mastopathy 10 55.2+5.4 2.3 +3.0
aBoth oestrogen and progesterone receptors present.
bBoth oestrogen and progesterone receptors absent.
added with 0.1% of bovine albumin serum. The
samples were then perfused with the same medium
which was gassed continuously with oxygen (95%)
and carbon dioxide (5%) at pH 7.4. After a 2.5h
wash-out period, a 1 h fraction was collected and its
contents of 6-keto-PGFlalpha and TxB2, the stable
hydration products of PGI2 and TxA2,
respectively, were measured by established
radioimmunoassays (Ylikorkala & Viinikka, 1982;
1980). The result was expressed as ng of
prostanoidmin-1 g-1 of tissue dry weight. The
storage of tissue in a frozen state did not affect the
PGI2 and/or TxA2 release, which was, however,
dose-dependently inhibited by the addition of
various PG synthesis inhibitors in the perfusion
buffer (Makilii et al., 1982).
To study the effect of medroxyprogesterone
acetate (MPA) on the tumour PGI2 and TxA2
production, tumour samples (4 receptor positive
and 4 negative) from 8 patients were cut into 5
identical pieces and perfused in the presence or
absence (controls) of MPA (Carlo Erba, Milan,
Italy) in concentrations of 100, 500, 1000 and
5000mgml- I for a period of lh after a 2.5 L wash-
out period. MPA was added into the perfusion
medium in ethanol, which was also added into the
control perfusion medium. Ethanol did not interfere
with the release of these prostanoids or with the
radioimmunoassays of 6-keto-PGFlalpha and TxB2
at the concentrations (0.5%) used in this work.
Moreover MPA did not interfere with the radioim-
munoassays employed in this study.
After the initial diagnosis the patients were
treated according to the guidelines generally
approved for the therapy of breast cancer. We were
able to follow them up to 3.7+0.7 years (mean+s.e.)
(Table I). During this time 15 patients developed
metastasis (axillary lymph nodes in 13, bone in 4,
skin in 3, lung in 2, the other breast in 2, brain in 1).
Two patients with receptor negative cancer died due
to breast cancer during the follow-up time.
The data were subjected after logarithmic
transformation to the paired and nonpaired t-test
and linear regression analysis.
Results
Breast cancer released more 6-keto-PGF1alpha and
TxB2 than did mastopathy (Table II). The rise in
TxB2 production was relatively greater than 6-keto-
PGFlalpha production, and consequently, the ratio
of 6-keto-PGFlalpha to TxB2 tended to be smaller
in breast cancer than mastopathy (Table II).
The production of neither 6-keto-PGFlalpha nor
TxB2 was related to the steroid receptor status or
the subsequent metastasis of the intial tumour
(Table III). Prostanoid production was greater in
more highly differentiated tumours than in
anaplastic ones although the difference reached
statistical significance only for TxB2 (Table III).
Two patients died due to the metastatic breast
cancer within 5 years of the initial diagnosis. Their
Table II Production of 6-keto-PGFlalpha and TxB2
(ngmin-Ig of dry weight tissue, mean+s.e.) in breast
cancer and mastopathy in vitro.
6-keto-
6-keto- PGFJalpha/
N PGFJalpha TxB2 TxB2
Breast cancer 23 4.5+0.9 2.5+0.9 2.6+0.4
Mastopathy 10 1.4+0.5 0.4+0.1 3.6+0.6
Significance P<0.025 P<0.0125 P<0.10
Table III Production of 6-keto-PGFlalpha and TxB2
(ngmin- g-1 tissue dry weight, mean+s.e.) in various
subgroups ofpatients with breast cancer
6-keto-
6-keto- PGFlalpha/
Subgroups N PGFJalpha TxB2 TxB2
Metastasis 15 4.8+1.3 2.9+0.9 1.6+1.5
No metastasis 8 4.1 +0.8 1.7+0.5 2.8+0.6
Poorly differ. 16 3.8+0.9 1.8+0.5 2.6+0.4
Well differentiated 7 6.2+2.0 4.1 + 1.4a 2.7+0.9
Ster. rec. posit. 11 3.8+0.8 2.6+0.8 2.5+0.5
Ster. rec. negat. 12 5.2+ 1.5 2.4+0.9 2.7+0.6
ap<0.05 in comparison with poorly differentiated.PROSTANOIDS IN BREAST CANCER 673
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Figure 1 The production of 6-keto-PGFlalpha (El)
and thromboxane B2 ({) in the presence of various
concentrations of medroxyprogesterone acetate (MPA)
as percentages (mean +s.e.) from the control values
(n for each=8) (The production of 6-keto-PFGlalpha
was 5.5+2.1 ngmin- g-1 and that of TxB2
3.5 +3.0ngminm- g- I in the control perfusion.)
mammary productions of 6-keto-PGFIalpha were
2.6 and 12.7ngmin -1 g-1 and those ofTxB2 1.4 and
11.7 gmin 1 g- 1, respectively.
MPA had no effect on 6-keto-PGFIalpha and
TxB2 production by the steroid receptor positive
and/or negative cancer (Figure 1).
Discussion
Substantial evidence suggests that the balance
between the systemic antiaggregatory prostacyclin
(PGI2) and proaggregatory thromboxane (TxA2) is
significant in tumour metastasis (Honn et al., 1981;
1983). This balance may also be an important
determinant inside the cancer cells, because only the
malignant cells which can bind platelets onto their
surface in the circulation, may form metastases
(Honn et al., 1983). Ductal breast cancer
metastasizes readily, and therefore we studied its
production of PGI2 and TxA2. It is very difficult
to obtain samples of normal ductal epithelium
therefore we used benign mastopathy as a control
tissue.
It is clear from our data that breast cancer tissue
produces more PGI2 and TxA2 than does
mastopathic tissue. Relatively, the rise in TxA2
production was greater than that of 6-keto-PGFl-
alpha, and therefore, the ratio of 6-keto-PGFlalpha
to TxB2 was decreased in breast cancer. Our
findings obtained by the tissue superfusion method
are in general agreement with the data of Karmali
et al. (1983) who extracted 6-keto-PGFlalpha and
TxB2 from breast cancer and who also demon-
strated the synthesis of those prostanoids in the
microsomal fraction of breast cancer cells. Bearing
in mind the overall stimulation in prostaglandin
synthesis by cancer cells including breast cancer
(Bennett, 1979) we may speculate that the cancer
cells themselves released increased amounts of 6-
keto-PGFlalpha and TxB2 in superfusion, although
a contribution by the inflammatory cells
unavoidably associated with cancer cells cannot be
excluded.
It has been proposed that the elevated
production of various classic prostaglandins could
be used as a marker of the high metastatic potential
for neoplastic cells in breast cancer (Bennett et al.,
1977; 1979; Rolland et al., 1980). In this regard,
PGI2 and TxA2 with their potent but opposing
effects on platelets, may be theoretically more
promising indices of metastatic capacity of the
primary cancer (Honn et al., 1981; 1983). We
followed our patients for a sufficiently long period
to assess the prognostic significance of PGI2 and
TxA2 production. There was no difference in the
production between patients with and without
subsequent metastasis. Moreover, the production
was similar in cancers with and without steroid
receptors, although the presence of these receptors
indicates a more favourable prognosis (Martin et
al., 1979), as is also evident from the present series.
These data may imply that the measurement of the
production of PGI2 and/or TxA2 by breast cancer
cannot be used as an indicator of the metastatic
potential of breast cancer.
High doses of MPA can be effective in the
treatment of advanced breast cancer, even in cases
which have failed to respond to other hormonal or
cytostatic agents (Mannes et al., 1976; Brunner et
al., 1977; Pannuti et al., 1978). The mechanism of
this action of MPA is not understood. In view of
the possible role of prostaglandins in cancer
(Bennett, 1979), we speculated that MPA could
change prostanoid production by the breast cancer
tissue and thereby reduce pain and improve the
outcome of patients with advanced disease (Mannes
et al., 1976; Brunner et al., 1977; Pannuti et al.,
1978). However, MPA at clinically achievable
(Hesselius & Johansson, 1981) or higher concen-
trations did not change the endogenous synthesis of
6-keto-PGFlalpha and TxB2 by receptor positive
or negative breast cancer. Therefore it seems likely
that the antitumour effect of MPA is not mediated
through prostanoids.
In conclusion, although human breast cancer
produces increased amounts of PGI2 and TxA2,
these do not seem to reflect the future tumour
behaviour.
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